A Repeat Dose Study to Investigate the Interaction of GSK2190915 on the Pharmacokinetics of Rosuvastatin
Status:
Completed
Trial end date:
2011-02-23
Target enrollment:
Participant gender:
Summary
Leukotrienes are potent inflammatory molecules produced mainly by mast cells, eosinophils,
monocytes/macrophage and neutrophils in response to allergic or inflammatory stimuli.
GSK2190915 is a high affinity 5-lipoxygenase-activating protein (FLAP) inhibitor that
attenuates the production of leukotrienes, through the blockage of the first committed step
in the leukotriene pathway, 5 lipoxygenase (5-LO) activation.
GSK2190915 has been shown to be an in vitro inhibitor of human organic anion transporting
polypeptides 1B1 and 1B3 (OATP1B1 and OATP1B3), hence there is a potential for a
pharmacokinetic drug-drug interaction with OATP1/ B1 substrates such as the anti-lipidemic
rosuvastatin.
This study will evaluate the effect of repeat oral dosing of GSK2190915 (30milligram (mg) and
100mg) on the steady-state pharmacokinetics (PK) of rosuvastatin (10 mg). In addition, the
study will evaluate the safety and tolerability of this combination when co-administered to
healthy, adult volunteers in two cohorts.